To see all protocols that comply with the WHO Essential Medicine List 

Check for clinical trials in this patient group. Link to Australian Clinical Trials website

This protocol is based on limited evidence; refer to the evidence section of this protocol for more information.

This protocol replaces a previous version ID 1671 Glioblastoma recurrent single agent lomustine with lomustine starting dose 130 mg/m2 which has been discontinued. It is the consensus of the eviQ reference committee to use a starting dose of 110 mg/m2 in this patient population based on the dose of lomustine used in recent clinical trialsrrr and due to toxicity concerns in these heavily pre-treated patients.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

19 Sep 2021